Erik Belleville
Sasol (Germany)(DE)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, PARP inhibition in cancer therapy
Most-Cited Works
- → Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network(2015)97 cited
- → Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status(2021)86 cited
- → Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis(2021)78 cited
- → Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry(2017)66 cited
- → Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry(2017)59 cited
- → Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany(2020)55 cited
- → Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network(2017)52 cited
- → Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis(2018)51 cited
- → Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry(2018)46 cited
- → Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study(2018)45 cited